Is XTL Biopharmaceuticals financially healthy?
Not really
XTL Biopharmaceuticals earns only -77.6 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDANet cash
Cash vs. debt$371,000 vs. $138,000
Current ratio0.6×Short-term assets for each $1 of bills due within a year
Interest coverage-77.6×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about XTL Biopharmaceuticals
Data as of Nov 13, 2026.